** Shares of drug developer Replimune Group REPL.O fall 76.5% to $2.90 premarket
** Co says the U.S. FDA declined to approve its experimental skin cancer drug, called RP1, for patients with advanced melanoma
** The FDA, in its so-called complete response letter, said the clinical trial to test the drug "was not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness"
** FDA said the trial cannot be adequately interpreted due to the heterogeneity of the patient population - REPL
** Co plans to urgently interact with the FDA to find a path forward
** Co was testing RP1 in combination with Bristol Myers Squibb's BMY.N Opdivo in patients with advanced skin cancer
** Up to last close, REPL up 1.8% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。